Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Pharmacogenet Genomics. 2010 Sep;20(9):569–572. doi: 10.1097/FPC.0b013e32833ca24b

Figure 1.

Figure 1

Weight change from baseline over the course of the 16-week trial for patients receiving (a) olanzapine or (b) risperidone. Weight change (y-axis) is expressed as the log of the ratio of weight at a given time point relative to baseline weight. Mean values for carriers of the DRD2 −141C deletion allele are depicted in red; non-carriers are depicted in black.